Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Univo Pharmaceuticals Ltd
  6. News
  7. Summary
    UNVO   IL0010935588

UNIVO PHARMACEUTICALS LTD

(UNVO)
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Can-Fite Biopharma Ltd. Announces New Pre-Clinical Findings in Connection with its On-Going Collaboration with Univo Pharmaceuticals

02/27/2020 | 06:00am EDT

Can-Fite BioPharma Ltd. announced new pre-clinical findings in connection with its on-going collaboration with Univo Pharmaceuticals, demonstrating CBD’s robust anti-neoplastic effect in pre-clinical studies against liver cancer. The studies were carried out on human liver cancer cells and utilized cannabinoid fractions enriched for CBD, in nano and pico molar concentrations. Marked inhibition of Hep-3b, liver cancer cell proliferation was noted and was mediated via the A3 adenosine receptor, the target of Can-Fite’s drug platform. Can-Fite is greatly encouraged and sees clinical potential in treating patients with minute CBD dosages which are effective and at the same time may minimize potential adverse effects. Based on this approach, an expansion of the agreement with Univo Pharmaceuticals has been entered into to allow the testing of minute CBD concentrations/dosages in combination with Namodenoson on liver cancer and additional oncological indications. As part of the expansion, Can-Fite will fund the research and development activities for the two new indications, to be jointly performed, for an amount of USD 200,000 per indication.


© S&P Capital IQ 2020
All news about UNIVO PHARMACEUTICALS LTD
08/31Univo Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended June 30, 202..
CI
2020Can-Fite Biopharma Ltd. Announces New Pre-Clinical Findings in Connection with its On-G..
CI
2020Can-Fite Biopharma Ltd and Univo Pharmaceuticals Ltd Collaboration Result in Discovery ..
CI
2019Univo Pharmaceuticals Ltd announced that it expects to receive ILS 5.994553 million in ..
CI
2019Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabin..
CI
2019Univo Pharmaceuticals Ltd announced that it expects to receive ILS 2.499999 million in ..
CI
2019Univo Pharmaceuticals Ltd announced that it has received ILS 3 million in funding
CI
2019UNV Medicine LTD. announced that it has received ILS 6 million in funding from Hagag Gr..
CI
2018UNV-Medicine Signs New Deal with Israeli Cannabis Startup
CI
2018UNV Medicine Ltd. completed the acquisition of D-Pharm LTD. in a reverse merger transac..
CI
More news
Financials
Sales 2019 0,82  0,26  0,26 
Net income 2019 -11,8 M -3,68 M -3,68 M
Net cash 2019 22,8 M 7,11 M 7,11 M
P/E ratio 2019 -5,92x
Yield 2019 -
Capitalization 73,0 M 22,8 M 22,8 M
EV / Sales 2018 -
EV / Sales 2019 35 568 323x
Nbr of Employees -
Free-Float 59,6%
Chart UNIVO PHARMACEUTICALS LTD
Duration : Period :
Univo Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Golan Bitton Chief Executive Officer & Director
Moran Yossef Chief Financial Officer
Chaim Hurvitz Chairman
Ilana Lavon Chief Scientific Officer
Omer Layani Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
UNIVO PHARMACEUTICALS LTD-9.57%23
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-38.86%25 233